ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $27.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 70.99% from the stock’s current price. Several […]

HC Wainwright reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Free Report) in a research note published on Monday morning, Benzinga reports. They currently have a $4.00 price objective on the stock. Several other brokerages have also recently weighed in on HOTH. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a […]